The market has been high on Bristol-Myers Squibb Co (BMY) stock recently. BMY gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With BMY Stock Today?
Bristol-Myers Squibb Co (BMY) stock is trading at $67.44 as of 2:32 PM on Thursday, Jun 10, a rise of $2.07, or 3.16% from the previous closing price of $65.38. The stock has traded between $65.42 and $67.70 so far today. Volume today is 9,190,971 compared to average volume of 10,168,108.
To screen for more stocks like Bristol-Myers Squibb Co click here.
More About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Click Here to get the full Stock Score Report on Bristol-Myers Squibb Co (BMY) Stock.
